The peptide combination of CJC-1295 and Ipamorelin represents one of the most studied pairings in growth hormone (GH) secretagogue research. Their distinct but complementary receptor mechanisms produce a synergistic amplification of pulsatile GH release that consistently exceeds the effect of either compound used in isolation — making this combination a valuable research model for studying the GH/IGF-1 axis.

CJC-1295: Extended-Action GHRH Analogue

CJC-1295 is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), engineered with a drug affinity complex (DAC) modification that covalently binds the peptide to circulating serum albumin. This conjugation extends plasma half-life from the native GHRH half-life of approximately 7 minutes to an estimated 6–8 days, enabling sustained stimulation of somatotroph cells in the anterior pituitary over an extended window.

Published clinical data report mean GH increases of 2–10 fold above baseline following CJC-1295 administration, with corresponding IGF-1 elevations sustained for up to 28 days post-dose. Critically, this elevation occurs across multiple natural GH pulses rather than producing a single supraphysiological spike — preserving a more physiological secretion pattern.

Ipamorelin: Selective Ghrelin Receptor Agonist

Ipamorelin is a pentapeptide that selectively agonises the ghrelin receptor (GHSR-1a) in pituitary somatotrophs. Its selectivity distinguishes it from earlier-generation GH secretagogues such as GHRP-6, which non-selectively stimulate cortisol and prolactin in addition to GH. Ipamorelin’s clean selectivity profile makes it a preferred research tool for isolating GH-specific effects without confounding hormonal signals.

Peak GH release in rodent models occurs approximately 30–45 minutes post-administration, producing a discrete, pulse-like secretion profile closely mimicking endogenous physiology.

Synergistic Mechanism

CJC-1295 acts via the GHRH receptor (Gs-coupled, cAMP pathway) to prime and sensitise pituitary somatotrophs, while Ipamorelin simultaneously activates GHSR-1a through the phospholipase C/IP3 pathway. The dual-receptor stimulation engages two independent intracellular signalling cascades, producing GH secretion measurably greater than additive — a true pharmacological synergy confirmed across rodent and non-human primate models.

Research Applications

This combination is routinely employed in preclinical studies modelling GH deficiency, age-related somatotropic decline, sarcopenia, and metabolic dysregulation. Researchers have used the pairing to examine downstream effects of sustained IGF-1 elevation on bone mineral density, lean tissue accretion, lipid metabolism, and tissue repair signalling.

CJC-1295 and Ipamorelin are research peptides not approved for human therapeutic use. All products are sold for laboratory research purposes only.

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide composed of 15 amino acids, originally derived from a protective protein isolated in gastric juice. Despite its relatively recent discovery, BPC-157 has accumulated a substantial body of preclinical research documenting its regenerative properties across diverse tissue types — ranging from tendons and ligaments to gastrointestinal mucosa and skeletal muscle.

Mechanism of Action

BPC-157 operates through several intersecting molecular pathways. Chief among these is its interaction with the growth hormone receptor system, particularly in fibroblasts and endothelial cells. Receptor sensitization leads to accelerated extracellular matrix remodelling — a prerequisite step in connective tissue repair. The peptide also modulates the nitric oxide (NO) pathway, stabilising endothelial NO production to promote angiogenesis without the oxidative burden associated with excess NO synthesis.

Additionally, BPC-157 has been shown to upregulate the expression of early growth response gene-1 (EGR-1), a transcription factor linked to tendon and ligament healing, as well as FAK and paxillin — proteins critical for cell survival and migration during wound healing.

Angiogenic Properties

Among BPC-157’s most reproducible effects is its promotion of angiogenesis. The peptide upregulates vascular endothelial growth factor (VEGF) and its primary receptor VEGFR2, stimulating the formation of new capillary networks in ischaemic or traumatised tissue. This vascularisation effect is considered a primary driver of the accelerated healing timelines observed in animal injury models.

Preclinical Observations

In rodent models of Achilles tendon transection, BPC-157 significantly reduced recovery time and restored tensile strength relative to saline controls. Comparable findings have been replicated in models of muscle tears, bone fractures, corneal injury, and intestinal anastomosis. The peptide consistently demonstrates an absence of detectable toxicity across studies — no LD50 has been established, and it shows no genotoxic or mutagenic activity in standard assays.

BPC-157 is being investigated exclusively in preclinical animal models. It is not approved for human therapeutic use. All products are sold for laboratory research purposes only.